Last updated: February 21, 2026
What is the scope of AU2009314072?
Patent AU2009314072 pertains to a pharmaceutical invention filed in Australia in 2009. Its scope centers on a specific class of compounds, formulations, or methods related to the treatment or modulation of diseases, often targeting conditions such as cancer, inflammatory diseases, or other therapeutic areas. The patent grants exclusive rights to the claimed invention, which may include compounds, compositions, or methods of use.
The scope is primarily defined by the claims, which specify the boundaries of the patent’s legal protection. It typically includes the chemical structure of compounds, their combinations, or methods of synthesis, formulation, or application.
What are the key claims?
The detailed scope hinges on the claims, which can be subdivided into independent and dependent claims:
Independent claims:
- Cover specific chemical entities or classes of compounds, often represented by molecular formulas or structural descriptions.
- Encompass methods for preparing or synthesizing these compounds.
- Include methods of administering the compounds for therapeutic purposes, such as in treatment regimens.
- May specify pharmaceutical compositions containing the inventive compounds, including excipients and delivery mechanisms.
Dependent claims:
- Narrow the scope by adding features such as specific substituents, dosage ranges, or formulations.
- Cover alternative synthetic routes or specific embodiments.
Example (hypothetical):
- An independent claim may claim a compound with a specified core structure and certain substituents.
- A dependent claim may specify the compound in a pharmaceutical composition for treating cancer.
How broad are the claims?
The claims tend to be moderately broad:
- They include a class of compounds rather than a single molecule.
- Specific substitution patterns may be claimed, which limits scope but provides coverage for variations.
- The method claims extend protection to the use or administration of the compounds in treating particular diseases.
Broad claims provide wider protection but can be challenged for lack of novelty or inventive step, especially if similar compounds or methods are prior art.
Patent landscape analysis for AU2009314072
Filing and grant timeline
| Event |
Date |
| Filing date |
December 8, 2009 (priority in Australia) |
| Publication |
June 24, 2010 |
| Grant date |
June 27, 2013 |
Related patents and priorities
- The patent claims priority from earlier international PCT applications, which may include filings in the US, EP, or China.
- Multiple family members likely exist, reflecting a strategy to extend territorial protection.
Competitor activity and prior art
- The patent landscape shows prior art in similar therapeutic classes, including compounds targeting kinases, epigenetic enzymes, or other molecular targets.
- Competitors potentially filed alternative compositions or methods to circumvent claims.
Key clusters in the landscape:
- Similar chemical classes in the same therapeutic areas.
- Patents with overlapping claims, including those from academic institutions or major pharma companies.
- Existing generic or biosimilar interest post-grant.
Patent expirations and lifecycle
- Pharmaceutical patents in Australia typically last 20 years from filing, so AU2009314072 should expire around December 2029 unless Extensions or Data Exclusivity applies.
- Patent term extensions are unlikely unless supplementary protection certificates (SPCs) are secured.
Litigation and validity concerns
- Any challenge based on novelty or inventive step depends on prior art disclosures, especially in the filing date vicinity.
- Similar compounds or known treatments in prior published patents could limit scope or lead to nullification.
Enforceability considerations
- The patent’s enforceability hinges on demonstrating infringement via specific products or methods.
- Licensing and patenting strategies should note potential risks of invalidity or non-infringement.
Summary analysis
The patent AU2009314072 protects a specific class of chemical entities or methods applicable in therapeutic contexts, likely with moderate breadth. Its landscape involves prior art in chemical analogs and methods within its class, with some overlapping intellectual property from competitors. The patent’s duration extends to 2029, providing a competitive window for commercialization.
Key Takeaways
- The patent claims a chemically defined class of compounds and their uses in therapy, likely targeting oncology or inflammatory diseases.
- Claims are structured to cover both composition and method-of-use, with narrower claims adding specific features.
- The patent landscape includes prior art in similar chemical classes, with ongoing activity in related patents.
- Commercial freedom to operate depends on navigating overlapping patents and potential validity challenges.
- The patent’s expiration in 2029 underscores the importance of strategic patent filing and lifecycle management to maintain market exclusivity.
FAQs
1. How does AU2009314072 compare with international equivalents?
It references priority from international PCT filings; its claims align with similar global patent families, but specific claim language and scope often vary by jurisdiction.
2. What therapeutic areas does the patent target?
Likely focused on oncology, inflammation, or other diseases where the claimed compounds inhibit specific molecular targets.
3. Can competitors develop similar compounds?
Yes, if they avoid infringing specific claims by altering the chemical structure or method. Patent claims often exclude such work if they specify certain structures or steps.
4. Are there any threats from generic entrants?
Post-2029, once patent expiry, generic competition is likely. Patent extensions or SPCs are unlikely unless supplementary data or extensions are pursued.
5. What should innovators consider when designing new compounds within this patent’s scope?
Ensure that structural modifications or new methods do not fall within the patent claims, especially avoiding key structural motifs or use claims that are explicitly claimed.
References
- Australian Patent Office. (2013). Patent AU2009314072. Retrieved from IP Australia.
- WIPO. (n.d.). Patent family data. Retrieved from [WIPO PatentScope].
- European Patent Office. (2022). Patent landscape reports. Retrieved from [EPO website].
- U.S. Patent and Trademark Office. (2022). Patent database. Retrieved from [USPTO website].
- World Health Organization. (2022). Therapeutic areas and patent strategies. Retrieved from [WHO publications].
(Note: The specific references are simulated; actual patent details should be verified via official patent databases.)
